Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1995 1
1996 2
1997 6
1998 2
1999 1
2000 3
2001 4
2002 4
2003 6
2004 10
2005 13
2006 15
2007 13
2008 17
2009 25
2010 17
2011 13
2012 24
2013 21
2014 23
2015 37
2016 28
2017 20
2018 25
2019 21
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

320 results
Results by year
Filters applied: . Clear all
Page 1
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, Gandhi S, Gupta R, Mates M, Moy B, Vandenberg T, Van Poznak CH. Dhesy-Thind S, et al. Among authors: Clemons MJ. J Clin Oncol. 2017 Jun 20;35(18):2062-2081. doi: 10.1200/JCO.2016.70.7257. Epub 2017 Mar 6. J Clin Oncol. 2017. PMID: 28618241 Review.
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. Baselga J, et al. Among authors: Clemons M. Lancet Oncol. 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30. Lancet Oncol. 2017. PMID: 28576675 Free PMC article. Clinical Trial.
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J. Campone M, et al. Among authors: Clemons M. Eur J Cancer. 2018 Nov;103:147-154. doi: 10.1016/j.ejca.2018.08.002. Epub 2018 Sep 18. Eur J Cancer. 2018. PMID: 30241001 Clinical Trial.
Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review.
Robinson A, Souied O, Bota AB, Levasseur N, Stober C, Hilton J, Kamel D, Hutton B, Vandermeer L, Mazzarello S, Joy AA, Fergusson D, McDiarmid S, McInnes M, Shorr R, Clemons M. Robinson A, et al. Among authors: Clemons M. Breast Cancer Res Treat. 2018 Oct;171(3):607-620. doi: 10.1007/s10549-018-4868-x. Epub 2018 Jul 4. Breast Cancer Res Treat. 2018. PMID: 29974358 Review.
PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer.
Dupuy F, Tabariès S, Andrzejewski S, Dong Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, Clemons M, Aguilar-Mahecha A, Basik M, Vincent EE, St-Pierre J, Jones RG, Siegel PM. Dupuy F, et al. Among authors: Clemons M. Cell Metab. 2015 Oct 6;22(4):577-89. doi: 10.1016/j.cmet.2015.08.007. Epub 2015 Sep 10. Cell Metab. 2015. PMID: 26365179 Free article.
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B. Van Poznak C, et al. Among authors: Clemons MJ. J Clin Oncol. 2017 Dec 10;35(35):3978-3986. doi: 10.1200/JCO.2017.75.4614. Epub 2017 Oct 16. J Clin Oncol. 2017. PMID: 29035643
Optimal sequence of adjuvant endocrine and radiation therapy in early-stage breast cancer - A systematic review.
McGee SF, Mazzarello S, Caudrelier JM, Lima MAG, Hutton B, Sienkiewicz M, Stober C, Fernandes R, Ibrahim MFK, Vandermeer L, Hilton J, Shorr R, Fergusson D, Clemons M. McGee SF, et al. Among authors: Clemons M. Cancer Treat Rev. 2018 Sep;69:132-142. doi: 10.1016/j.ctrv.2018.06.015. Epub 2018 Jun 28. Cancer Treat Rev. 2018. PMID: 30014951 Review.
Surviving Surveys.
Mazzarello S, Clemons M, Graham ID, Jacobs C. Mazzarello S, et al. Among authors: Clemons M. J Oncol Pract. 2015 Jan;11(1):44-6. doi: 10.1200/JOP.2014.001484. Epub 2014 Aug 5. J Oncol Pract. 2015. PMID: 25095823 No abstract available.
Should de-escalation of bone-targeting agents be standard of care?
Awan A, Hutton B, Clemons M. Awan A, et al. Among authors: Clemons M. Ann Oncol. 2018 May 1;29(5):1333-1334. doi: 10.1093/annonc/mdy068. Ann Oncol. 2018. PMID: 29529190 Free article. No abstract available.
320 results
Jump to page
Feedback